CorMedix (CRMD) announced that it intends to offer and sell $85M of shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by CorMedix. CorMedix intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, expenses related to research and the development of product candidates, and potential strategic transactions, including acquisitions, joint ventures or collaborations, involving companies, products or assets that complement CorMedix’s business. RBC Capital Markets is acting as sole bookrunner for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix’s Promising Growth: Buy Rating Backed by Strong DefenCath Launch and Strategic Partnerships
- CorMedix Holds Annual Stockholders Meeting, Approves Key Proposals
- CorMedix Expands DefenCath Implementation with Major Client
- CorMedix price target raised to $20 from $15 at Needham
- Cormedix’s Growth Potential Bolstered by Expanded LDO Agreement and Increased Sales Guidance, Despite TDAPA Reimbursement Risks